LIEBERMAN GERALD M 4

What Happened

• Gerald M. Lieberman, a director of Teva Pharmaceutical Industries Ltd. (TEVA), received a grant of 7,242 restricted share units (RSUs) on May 28, 2026. The Form 4 reports the acquisition as a derivative award at $0.00 per unit (i.e., a grant rather than a purchase).
• The RSUs vest on May 28, 2027. The filing does not state a cash value; actual dollar value will depend on Teva’s ordinary share (or ADS) price at settlement.

Key Details

• Transaction date: May 28, 2026; Form 4 filed June 1, 2026.
• Quantity: 7,242 restricted share units; reported acquisition price: $0.00 (award).
• Vesting: RSUs vest on May 28, 2027 (one-year vest).
• Footnotes: Each RSU represents a contingent right to one ordinary share or, at the committee’s option, the cash value of one ordinary share. Ordinary shares may be represented by American Depositary Shares (each currently represents one ordinary share).
• Shares owned after transaction: Not disclosed on this Form 4.
• Filing timeliness: The Form 4 covers the May 28, 2026 grant and was filed June 1, 2026; the filing does not indicate any special tardiness notation.

Context

• RSU grants are common director compensation and are a deferred equity award rather than an immediate purchase or sale. They do not by themselves indicate buying or selling pressure until shares are settled or sold.
• At settlement (post-vesting), the RSUs will convert to ordinary shares or cash, depending on the committee’s choice and plan terms.